SCOLR updates
This article was originally published in The Tan Sheet
Executive Summary
UPM Pharmaceuticals has agreed to manufacture SCOLR Pharma's controlled delivery technology (CDT) 24-hour OTC pseudoephedrine, SCOLR announces June 6. The Bellevue, Wash.-based firm says it plans to use the UPM-produced PSE tablets in studies to support an NDA, to be submitted to FDA in 2006. UPM also will produce several of SCOLR's other products currently in development, including CDT 12-hour ibuprofen, 12-hour pseudoephedrine and a CDT-based osteoporosis drug raloxifene (Eli Lilly's Evista). Clinical testing has already been initiated for the 12-hour ibuprofen, the company reports...
You may also be interested in...
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.